Keyword: Indivior

Indivior made billions from fraudulent marketing of its opioid dependence drugs, the feds allege in a new indictment.

Takeda pulls an FDA filing for Ninlaro and is ordered to pay $155 million in a Shire patent case; a cancer startup gets Chinese investors' attention.

Indivior has been fighting off generics to top-selling Suboxone, but an appeals court has unleashed copycats now charging toward launches next week.

Indivior's Perseris launch timing is up in the air amid a slow rollout of fellow newcomer, Sublocade, and a heated Suboxone patent fight.

Opdivo is the first I-O drug approved in China; Dr. Reddy's faces Suboxone Film patent spat; former multinational pharma executives jump to Chinese startups.

Dr. Reddy's moved ahead with an "at risk" launch of Indivior's top drug, but now a court has put the rollout on hold.

Competition and legal holdups threaten to stifle the launch of Mylan's generic version of of sublingual Suboxone.

Already under fire from U.S. authorities and others, Indivior faces new legal scrutiny from officials in California.

Thirty-five U.S. states and the District of Columbia have filed suit against the U.K.'s Indivior, alleging anticompetitive actions for the opioid Suboxone and seeking to “disgorge” the company's "ill-gotten” gains.